Trial Profile
Multicenter, Open-Label, Single Arm Phase II Clinical Trial of Dasatinib in the Treatment of Systemic Mastocytosis.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Jan 2020
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Systemic mastocytosis
- Focus Biomarker; Therapeutic Use
- 24 Mar 2012 Actual initiation date (22 Jan 2010) added as reported by European Clinical Trials Database.
- 24 Mar 2012 Status changed from not yet recruiting to recruiting as reported by European Clinical Trials Database.
- 24 Mar 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2008-006183-11).